Question explored with the scientific record
Stem cell treatments for Multiple
Stem cell therapy for MS is not one treatment. The strongest evidence is for a harsh immune reset (aHSCT), not for the clinic-selling "mesenchymal stem cell" infusions.
The real evidence is autologous hematopoietic stem cell transplant, aHSCT: chemo wipes out the immune system, then your own stem cells are put back. In 764 patients, 68% were free of disease activity at 5 years and 23.3% had disability progression [5]. Treatment-related death fell to 0.3% after 2005 and 0% with low-intensity regimens [5]. That is a genuine effect, but it is a punishing procedure with real mortality, and the evidence is largely single-arm, not a randomized trial against the best drugs [4][5].
The mesenchymal stem cell (MSC) infusions sold in clinics are a different story. The human trials are tiny, open-label, and uncontrolled: 22 patients here [3], 18 there [2], 10 in another [3]. Without a control group, improvements cannot be attributed to the cells [3]. The mouse data show benefit [1][3], but mouse MS is not human MS.
| Therapy | Best human evidence | Control group? |
|---|---|---|
| aHSCT | 68% NEDA at 5 yr, 764 pts [5] | Mostly no |
| MSC infusion | 18 pts, EDSS 5.23 to 4.62 [2] | No |
| MSC intrathecal | 22 pts, 27% new lesions [3] | No |
My call: aHSCT is a real but aggressive option for aggressive MS, best done in a trial or specialist center; clinic MSC infusions are unproven and should not be bought as treatment. Confidence: moderate on aHSCT, low on MSCs.
Sources used 5
-
Mesenchymal properties of SJL mice-stem cells and their efficacy as autologous therapy in a relapsing–remitting multiple sclerosis model
This study compares adipose-derived mesenchymal stem cells (Ad-MSCs) from two mouse strains (SJL/JCrl and C57BL/6) under identical culture conditions, showing similar MSC properties and demonstrating that autologous Ad-MSC therapy attenuates disease severity and pathology in rel…
DOI: 10.1186/scrt524 -
Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis
This study investigates the safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells (UCMSC) in treating multiple sclerosis, demonstrating significant improvements in disability scores and quality of life without serious adverse events.
DOI: 10.1186/s12967-018-1433-7 -
Cell-Based Therapeutic Strategies in Multiple Sclerosis
Mesenchymal stem cell transplantation is safe and tolerable in multiple sclerosis, with early phase I/II trials showing possible functional and MRI benefits but no established efficacy.
DOI: 10.17925/enr.2014.09.01.37 -
Progress and prospects for the use and the understanding of the mode of action of autologous hematopoietic stem cell transplantation in the treatment of multiple sclerosis
An expert commentary reviewing the progress, mechanisms, regimens, and clinical implications of autologous hematopoietic stem cell transplantation (AHSCT) for multiple sclerosis, highlighting potential suppression of CNS inflammation and possible disability reversal alongside th…
DOI: 10.1080/1744666X.2017.1297232 -
Autologous hematopoietic stem cell transplantation for MS
This study evaluates the safety and efficacy of autologous hematopoietic stem cell transplantation (aHSCT) for multiple sclerosis (MS), suggesting it may be safer and as effective as current disease-modifying drugs.
DOI: 10.1212/WNL.0000000000003995